icsi versus conventional ivf in non-male factor couples

Conditions: Infertility

Summary: conventionally, icsi was initially developed and has been shown to be an effective treatment for male factor infertility. it is increasingly being used for patients without a male factor diagnosis, despite the lack of clinical evidence to support its use. moreover, icsi is an invasive and expensive procedure. this multi-center, randomized, controlled, parallel-group trial will be conducted to compare the effectiveness of icsi versus conventional ivf in infertile couples scheduled for ivf treatment, in whom the male partner has normal sperm.

all patients undergoing ivf/icsi will be treated with a gnrh antagonist protocol. recombinant fsh (puregon, msd) will be given on day 2 or day 3 of menstrual cycle for 5 days. the starting dose is individualized for each patient based on the following criteria: amh \ 2.1 ng/ml, dose 150 iu/day. after that, investigators can titrate the dose based on their clinical judgment. follicular development will be monitored by ultrasound scanning and measurement of estradiol and progesterone levels, starting on day 5 of stimulation. scanning and hormonal measurement will be repeated every 2 to 3 days, depending on the size of follicles. an antagonist is routinely used on day 5 until the day of triggering. criteria for triggering, by hcg (ovitrelle 250 mg, merck, germany) will be the presence of at least three leading follicles of 17 mm. in women with excessive follicular response (≥15 follicles ≥12 mm), 0,2 mg triptorelin (diphereline, ipsen beaufour, france) will be used when there are at least two leading follicles of 17 mm. oocyte retrieval will be performed 36 hours after triggering. randomization and allocation of participants to study groups will be performed on the day of egg pick up, after having obtained the semen from the husband. eligible participants that have provided informed consent will be randomised to either icsi or conventional ivf. in icsi group, insemination will be performed by using icsi, 3 - 4 hours after oocyte retrieval. occs will be stripped by using hyaluronidase. only matured oocytes will be inseminated. in conventional ivf group, insemination will be performed by conventional ivf. two hours after retrieval, collected occs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. inseminated occs will be cultured overnight in culture medium. in both groups, fertilization check will be performed under inverted microscope at period of 16-18 hours after insemination. on day 3, embryo evaluation will be performed at fixed time point 66±2 hours after fertilization, using the istanbul consensus. embryo transfer will be performed on day 3 under ultrasound guidance. a maximum of 2 embryos will be transferred into the uterus. the remaining grade 1 and 2 embryos will be frozen. luteal-phase support will be done with estradiol (valiera 2mg) 8mg/day and vaginal progesterone 800mg/day (cyclogest 400mg) until 7th week of gestation. if there are contra-indications for fresh embryo transfer, a freeze-all strategy will be applied, using cryotech technique. indications for freeze-all include: risk of ovarian hyperstimulation syndrome (ohss), premature progesterone rise (≥1.5 ng/ml), thin endometrium (\<7 mm), fluid in cavity on day of embryo transfer, endometrial polyp, hydrosalpinx that have not removed before oocyte retrieval. in the next cycle, endometrium will be prepared by using estradiol (valiera 2 mg, 8 mg/day) orally, starting from day 2-3 of menstrual cycle. when the endometrium thickness reaches 8 mm or more, patients will start using progesterone vaginally (cyclogest 400 mg, 800 mg/day). embryo transfer will be performed 3 days after using progesterone. on the day of embryo transfer, embryos will be thawed. in the frozen/thawed cycle, the best embryos will be utilized first, as in fresh transfer. two hours after thawing, a maximum of 2 surviving embryos will be transferred into the uterus under ultrasound guidance. luteal phase support will be provided with estradiol (valiera 2mg) 8mg/day and vaginal progesterone 800 mg/day (cyclogest 400 mg) until the seventh week of gestation. in both groups, clinicians who perform embryo transfer, either fresh or frozen cycles, will be blinded to the intervention. a serum hcg will be measured 2 weeks after embryo transferred, and if positive, an ultrasound scan of the uterus will be performed at gestational weeks 7 and 12. at 11 - 12 weeks of gestation, participants will be referred to the outpatient clininc, o\&g department, my duc hospital or an sinh hospital for prenatal care until giving birth.

Eligibility criteria:
inclusion criteria: * having ≤ 2 ivf/icsi cycles * total sperm count and motility are normal (who, 2010) * antagonist protocol * agree to have ≤ 2 embryos transferred * not participating in another ivf study at the same time exclusion criteria: * in-vitro maturation (ivm) cycles * using frozen semen * poor fertilization in previous cycle (≤ 25%)

Keywords: icsi conventional ivf non-male factor